Chimeric Therapeutics Ltd has released a press release.
Follow up period completed for 3rd cohort in CHM 1101 trial
Filed with ASX ·
6ix hasn’t read this filing yet.
Chimeric Therapeutics Limited on 6ix
Earlier from Chimeric Therapeutics
- Dosing complete in 3rd cohort of CHM 1101 (CLTX CAR T) trial
- Exclusive license agreement with CWRU for CORE-NK platform
- Patent received in Japan for CLTX CAR technology
- Licenses viral vector technology from Penn for CDH17
- A$30 million Equity Placement Agreement with L1 Capital
Later from Chimeric Therapeutics
- Chimeric receives $3.06M R&D tax incentive
- Appendix 4D and Half Year Report
- Fourth dose cohort initiated in CHM 1101 Phase 1 trial
- Positive pre-IND meeting with FDA for Phase 1 CAR T study
- CHM 1101 GBM Abstract Accepted for ASCO 2023 Presentation
Follow Chimeric Therapeutics into a list and get an email when it puts out news.
Follow Chimeric Therapeutics